


## Nesolicaftor

<b>Cat. No.:</b>	HY-111680		
<b>CAS No.:</b>	1953130-87-4		
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>18</sub> N <sub>4</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	354.36		
<b>Target:</b>	CFTR; Autophagy		
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Autophagy		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 250 mg/mL (705.50 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
<b>Preparing Stock Solutions</b>	<b>1 mM</b>	2.8220 mL	14.1099 mL	28.2199 mL
	<b>5 mM</b>	0.5644 mL	2.8220 mL	5.6440 mL
	<b>10 mM</b>	0.2822 mL	1.4110 mL	2.8220 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.08 mg/mL (5.87 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.87 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.08 mg/mL (5.87 mM); Clear solution</li> </ol>			

### BIOLOGICAL ACTIVITY

<b>Description</b>	Nesolicaftor (PTI-428) is a specific cystic fibrosis transmembrane conductance regulator (CFTR) amplifier <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	CFTR <sup>[1]</sup>
<b>In Vitro</b>	Nesolicaftor (PTI-428) (30 μM, 24 h) can increase CFTR function, such as causing a larger change in inh-172 in 16HBE14o-cells expressing G542X-CFTR, also can increase in F508del-CFTR function of CFBE41o-cells expressing F508del-CFTR in a dose-dependent manner <sup>[2]</sup> .

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

---

- Int J Mol Sci. 2022 Sep 19;23(18):10956.
- J Cyst Fibros. 2020 Jul 14;S1569-1993(20)30795-5.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Arianna Venturini, et al. Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene. Int J Mol Sci. 2021 Nov 4;22(21):11972.
- [2]. Mijnders M, et al. Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis. Curr Opin Pharmacol. 2017 Jun;34:83-90.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA